BAAM
VIR icon

Baker Avenue Asset Management’s Vir Biotechnology VIR Stock Holding History

Baker Avenue Asset Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100
Closed -$937 – 1456
2023
Q3 		$937 Buy
+100
New +$1.43K ﹤0.01% 1294

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Baker Avenue Asset Management's VIR Position: Q4 2023 in Review

Baker Avenue Asset Management sold out of Vir Biotechnology (VIR) in Q4 2023, closing a stake of 100 shares — an estimated $937 sold.

Baker Avenue Asset Management first reported a position in VIR in Q3 2023 and held it in 1 quarter. The position peaked at $937 in Q3 2023. 206 funds tracked by Wall St. Rank hold VIR as of Q4 2023.

  • Baker Avenue Asset Management reported no remaining Vir Biotechnology position as of Q4 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 100 Vir Biotechnology shares in Q4 2023, an estimated $937.
  • Baker Avenue Asset Management first reported a position in Vir Biotechnology in Q3 2023 and held it in 1 quarter.
  • Baker Avenue Asset Management's Vir Biotechnology position peaked at $937 in Q3 2023.
  • 206 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2023.

Based on Baker Avenue Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.